Hsbc Holdings PLC Has $35.42 Million Stake in Insulet Corporation $PODD

Hsbc Holdings PLC reduced its stake in Insulet Corporation (NASDAQ:PODD) by 32.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 124,514 shares of the medical instruments supplier’s stock after selling 59,379 shares during the period. Hsbc Holdings PLC owned approximately 0.18% of Insulet worth $35,424,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Larson Financial Group LLC lifted its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the 4th quarter worth $26,000. Elyxium Wealth LLC bought a new position in shares of Insulet in the fourth quarter worth $28,000. DV Equities LLC acquired a new position in Insulet in the fourth quarter valued at about $28,000. Finally, MV Capital Management Inc. acquired a new position in Insulet in the fourth quarter valued at about $29,000.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.36% of the stock is currently owned by insiders.

Analyst Ratings Changes

PODD has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet in a research report on Tuesday. They set a “buy” rating and a $190.00 price objective for the company. Weiss Ratings cut shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. BTIG Research cut their price target on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Robert W. Baird reduced their price target on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Finally, Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Twenty-two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $238.67.

Insulet Stock Performance

Insulet stock opened at $143.90 on Wednesday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The stock has a market cap of $9.97 billion, a PE ratio of 33.47, a P/E/G ratio of 1.09 and a beta of 1.13. Insulet Corporation has a 12-month low of $138.79 and a 12-month high of $354.88. The business’s 50-day moving average price is $161.91 and its two-hundred day moving average price is $223.32.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the business earned $1.02 earnings per share. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.